A multinational multicentre randomised paralle group study on therapeutic efficacy and tolerability of PIASCLEDINE capsules 300 mg in comparison with placebo in the treatment of hip osteoarthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000979-33-IT

Enrollment

196

Registered

2006-01-24

Start date

2005-01-31

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hip osteoarthritis MedDRA version: 6.1 Level: PT Classification code 10031161

Interventions

Trade Name: PIASCLEDINE Pharmaceutical Form: Capsule, hard Current Sponsor code: piascledine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300-

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026